Engineering an in vivo charging station for CAR-redirected invariant natural killer T cells to enhance cancer therapy

By afschroeder • March 19, 2026

Li YR, Nan H, Liu Z, Fang Y, Zhu Y, Lyu Z, Shao Z, Zhu E, Zhang B, Yang Y, Shen X, Chen Y, Hsiai T, Yang L, Li S. Engineering an in vivo charging station for CAR-redirected invariant natural killer T cells to enhance cancer therapy. Nat Biomed Eng. 2026 Mar 17. doi: 10.1038/s41551-026-01629-3. Epub ahead of print. PMID: 41845089.

Tags: Cardiology/Epi, Publications, Veterans Administration

Outcome of Patients Presenting With High-Risk Pulmonary Embolism Treated With Mechanical Thrombectomy: A Subgroup Analysis From the STRIKE-PE Study

Sharp ASP, Dohad SY, Weinberg I, Kurzyna M, Davis HC, Stepniewski J, Perkowski PE, Holden A, West FM, Keeling WB, Parikh SA, Moriarty JM. Outcome[...]

Glucagon-Like Peptide 1 Receptor Agonists are Associated With Reduced Risk of Hepatic Encephalopathy in Cirrhosis

Singh V, Wang M, Ebinger J, Velazquez A, Cheng S, Kwan AC, Trivedi HD. Glucagon-Like Peptide 1 Receptor Agonists are Associated With Reduced Risk of[...]

Temporal Trends and Future Projections of Pulmonary Embolism and Top Contributing Causes of death in the United States, 1968-2040: insights from the CDC WONDER database

Khan S, Abbas F, Hassan M, Hussain M, Ahmed M, Ahsan A, Qureshi S, Khalid N, Sajjad A, Baig M, Waqas SA, Fonarow GC, Greene[...]